| Biomarker ID | 1820 |
| PMID | 30470249 |
| Year | 2018 |
| Biomarker | HOXD3+GSTP1 |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Urine |
| Subjects | Humans |
| Regulation | Methylated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include (GSTP1): Pathways include: Biological oxidations, Metapathway biotransformation, Pathways in cancer, T cell receptor regulation of apoptosis, Metabolism Pathways include (HOXD3): T cell receptor regulation of apoptosis |
| Experiment | Benign Vs High CAPRA Score |
| Type of Biomarker | Diagnostic |
| Cohort | 408 patients were selected for the study. Training Cohort consisted of 123 benign samples, 145 PCa samples. Validation Cohort consisted of 59 benign samples and 81 PCa samples. Training and testing cohort were divided in 1:3 ratio |
| Senstivity | 57.1% |
| Specificity | 97% |
| AUC | 0.795 (95% CI: 0.758-0.891) |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | Quantitative MethyLight assay |
| Clinical | No |
| Remarks | Recently developed UCSF Cancer of the Prostate Risk Assessment (CAPRA) score is more informative due to ease of calculation and inclusion of key clinical variables including age, PSA, percent of cores positive in biopsy (%core), clinical T stage, and Gleason patterns. |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |